Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia
- 1 December 2002
- journal article
- clinical trial
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 50 (6) , 497-500
- https://doi.org/10.1007/s00280-002-0539-y
Abstract
Purpose. Mylotarg, a humanized anti-CD33 antibody linked to an antitumor antibiotic, is approved for the treatment of patients with relapsed acute myeloid leukemia (AML). Topotecan and cytarabine (ara-C) is an effective anti-AML regimen. A pilot study of Mylotarg combined with topotecan and ara-C (MTA) was conducted in patients with refractory AML. Methods. MTA consisted of Mylotarg 9 mg/m2 intravenously (i.v.) over 2 h on day 1, ara-C 1 g/m2 over 2 h i.v. on days 1 through 5, and topotecan 1.25 mg/m2 by continuous infusion i.v. on days 1 through 5. Results. A group of 17 patients (9 primary resistant, 8 relapsed) with AML or advanced myelodysplastic syndrome (MDS) received 20 courses of MTA. The median age of the patients was 55 years (20–70 years). Two patients (12%) achieved complete remission. The median overall survival was 8.2 weeks. Five patients (29%) developed grade 3/4 hepatic transaminitis, including one patient (6%) who died with hepatic venoocclusive disease. Conclusions. MTA was moderately effective and associated with significant toxicity in patients with refractory AML.Keywords
This publication has 0 references indexed in Scilit: